256
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Reporting patterns of adverse drug reactions over recent years in China: analysis from publications

, , , , , , , , & (Professor) show all

References

  • WHO Collaborating Centre for International Drug Monitoring. The importance of pharmacovigilance. World Health Organization, Geneva; 2002
  • Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf 2012;35(12):1171-82
  • Sharma M, Gupta S. Postmarketing surveillance. In: Gupta SK, editor. Textbook of pharmacovigilance. Jaypee Brothers; New Delhi: 2011
  • Uppsala Monitoring Centre. VigiBase reaches 9 million reports. 2014. www.who-umc.org/DynPage.aspx?id=105196&mn1=7347&mn2=7489&mn3=7248&newsid=11561 [Accessed 23 June 2014]
  • Olsson S, Pal SN, Stergachis A, et al. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf 2010;33(8):689-703
  • Zhang L, Wong LY, He Y, et al. Pharmacovigilance in china: current situation, successes and challenges. Drug Saf 2014;37(10):765-70
  • China Food and Drug Administration. CFDA releases 2013 Annual Report for National Adverse Drug Reaction Monitoring. 2014. Available from: www.sda.gov.cn/WS01/CL0078/99794.html [Accessed 14 May 2014]
  • China Food and Drug Administration. 2014. Available from: www.sda.gov.cn/WS01/CL0001/ [Accessed 6 June 2014]
  • National Center for ADR Monitoring, China. Available from: www.cdr.gov.cn/ [Accessed September 2014]
  • China Food and Drug Administration. SFDA releases 2009 Annual Report for National Adverse Drug Reaction Monitoring. 2010. Available from: www.sda.gov.cn/WS01/CL0051/48201.html [Accessed 6 March 2013]
  • China Food and Drug Administration. SFDA releases 2010 Annual Report for National Adverse Drug Reaction Monitoring. 2011. Available from: www.sda.gov.cn/WS01/CL0051/60952.html [Accessed 6 March 2013]
  • China Food and Drug Administration. SFDA releases 2011 Annual Report for National Adverse Drug Reaction Monitoring. 2012. Available from: www.sda.gov.cn/WS01/CL0051/72190.html [Accessed 6 March 2013]
  • China Food and Drug Administration. SFDA releases 2012 Annual Report for National Adverse Drug Reaction Monitoring. 2013. Available from: http://app1.sfda.gov.cn/WS01/CL0051/79058.html [Accessed 15 March 2013]
  • Wang D, Cheng G. Annual trend analysis of adverse drug reaction data. Chin J Pharmacoepidemiol 22(5):238-41
  • MHRA. Drug Alerts. 2014. Available from: www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/index.htm [Accessed 6 September 2014]
  • FDA. Reports Received and Reports Entered into FAERS by Year. 2014. Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm [Accessed 5 September 2014]
  • FDA. FDA Adverse Event Reporting System (FAERS). 2014. Available from: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm [Accessed 6 September 2014]
  • Uppsala Monitoring Centre. Uppsala Reports 63. In: Centre UM, editor. Uppsala Monitoring Centre; Sweden: 2013. 7
  • MHRA MHRA annual statistics 2010/11
  • MHRA Credit card sized information card on Yellow Card reporting for healthcare professionals. 2010. Available from: https://yellowcard.mhra.gov.uk/_assets/files/Healthcare-Professional-Information-Card.pdf [Accessed 6 September 2014]
  • Health Canada. Adverse reaction and incident reporting-2011. Can Adverse React Newsl 2012;22(3):3-6
  • Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 32(11):1067-74
  • Fortnum H, Lee AJ, Rupnik B, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther 37(2):161-5
  • Tang JL, Liu BY, Ma KW. Traditional Chinese medicine. Lancet 2008;372(9654):1938-40
  • Zhang L, Yan J, Liu X, et al. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. J Ethnopharmacol 2012;140(3):519-25
  • Wang H, Ye X, Gao Q, et al. Pharmacovigilance in Traditional Chinese Medicine safety surveillance. Pharmacoepidemiol Drug Saf 2009;18(5):357-61
  • BI F, zhang L. Discussion on the Safety of Traditional Chinese Medicine Injection. Chin J Pharmacol 2012;9(2):89-92
  • Becker ML, Visser LE, van Gelder T, et al. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging 25(2):145-52
  • Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 25(4):343-55
  • Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, et al. Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol 2012;68(12):1667-76
  • Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf 2012;35(9):769-81
  • Bian ZX, Tian HY, Gao L, et al. Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica. J Evid Based Med 3(1):5-10
  • Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009;18(6):427-36
  • Copas JB, Hilton FJ. Record linkage: statistical models for matching computer records. J R Stat Soc Ser A Stat Soc 1990;153(3):287-320
  • Roland GN, Andrew B. A Hit-Miss Model for Duplicate Detection in the WHO Drug Safety Database. Proceedings of the eleventh ACM SIGKDD international conference on Knowledge discovery in data mining; Chicago, Illinois USA; 2005. p. 459-68
  • WHO. A practical handbook on the pharmacovigilance of antimalarial medicines. WHO; Geneva: 2008
  • WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. WHO; Geneva: 2009
  • WHO. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis. WHO; Geneva: 2012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.